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Abstract
A long list of chemotherapeutical drugs used in the treatment of the peripheral and the central nervous systems possess
anti-microbial activity. Some of these neurotropic compounds are chiral, with the one stereo isomeric form exaggerating
reduced neurotropism. This is the case for the levorotatory form of thioridazine. The phenothiazine thioridazine is an
interesting compound, characterized by exhibiting a significant growth inhibiting activity on a wide array of micro-
organisms. Thioridazine is characterized by another challenging feature, because the compound is concentrated in certain
human tissue cells. The present study describes a comparative study of the two enantiomers as well as the racemic form of
thioridazine. The study exploits the stereochemical aspect and the in vitro and in vivo potential of these compounds, with a
focus on the effects on Gram negative organism Salmonella enterica serover Typhimurium. In summary, the results of this
study yielded a significant antibacterial activity of all forms of thioridazine, indicating the levorotatory (–)- form to be
superior in terms of both its in vitro and in vivo efficacies.
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Introduction
An antibiotic may be defined as a product from a microorganism
capable of inhibiting the growth of another microorganism at
distinctly low levels. The chemotherapeutics, on the other hand, are
primarily synthetic compounds that are able to act on microorgan-
isms inavery similarmanner, but atmuchhigher concentrations. It is
now known that both antibiotics and antibacterial chemotherapeu-
tics have lost the battle to a large extent in the fight against multidrug
resistant (MDR) bacterial pathogens. However, intensive studies by
various groups of scientists throughout the world have revealed that
therearemedicinal compoundsused for the therapyofnon-infectious
pathology possess distinct antimicrobial properties [1–13]. These
compounds are termed as non-antibiotics [10]. Non-antibiotics
exhibit properties that render them important for the therapy of
different MDR infections. Phenothazines being one of the most
important group of non-antibiotics have been studied extensively for
their antimicrobial potentiality [1–13,14]. These non-antibiotics
possessmostof thecharacteristicsofantibioticsandtheirantibacterial
action can be further potentiated by suitable combinations [15–18].
The phenothiazine thioridazine (Tz) is a unique non-antibiotic
which is highly bactericidal for Gram positive bacteria and acts as
a bacteriostatic agent against Gram negative organisms [19].
Thioridazine is chiral and previous studies have reported that the
levorotatory form (2) thioridazine is concentrated in human tissue
cells at higher levels than the dextrorotatory form (+) [20].
Furthermore the (–) form of Tz has been reported to have less
challenging pharmaco-dynamic activity, e.g. reduced blocking
activity on centrally located dopamine D2-receptors than the (+)-
form [21]. Several in vitro studies have shown another feature of
racemic Tz.
The compound is concentrated in human macrophages and
different tissue types, such as pulmonary epithelial cells.
Racemic Tz has a great potentiality for the therapy of MDR-
tuberculosis since this compound is concentrated 100-fold in the
human macrophages where the tubercle bacilli multiply and
remain viable and where antibiotics fail to enter [22]. Furthermore
racemic Tz has been shown to possess the capacity to lower the
invasion ability of Gram positive and Gram negative bacteria in
human epithelial cell lines [23]. Moreover racemic Tz proved to
be highly efficient in disintegrating the invading cells of Salmonella
enterica serover Typhimurium in mice at rather low levels [21]. The
present study aims to define the specific antibacterial properties of
the enantiomeric forms of thioridazine, e.g. the racemic, the (+)-
and the (–)- compounds and clarify, whether there is a difference in
the efficacy of the drug based on its stereoisomeric profile. In order
to achieve this goal, we performed comparative in vitro and in vivo
studies with two enantiomers along with the racemic compound
available commercially (Sigma Chemicals, Denmark).
Materials and Methods
Bacteria
A total of 55 different bacteria belonging to both Gram positive
and Gram negative types were taken for this study (Table 1).
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Drugs
Racemic thioridazine (Sigma Chemicals, Denmark). The two
enantiomers of thioridazine were prepared according to the
procedure of Bourquin et al [22].
Media
Liquid media were nutrient broth (NB; Oxoid), peptone water
(PW) containing 1.0% peptone (Oxoid) and 0.5% NaCl and
Mueller Hinton broth (MHB, Oxoid). Solid media were nutrient
Table 1. Minimum inhibitory concentration (MIC) of three optical forms of Tz with respect to different bacteria.
BACTERIA MIC(mg/ml)
Racemic (+) (2)
S. aureus NCTC 6571, V. cholerae 569B, V. cholerae 1023 25 25 25
S. aureus NCTC 8530, S. aureus ATCC 25923, S. dysenteriae 7 NCTC 519, Sh. boydii NCTC 254, V.cholerae ATCC 14033,
ATCC 14035, V. cholerae DN7
50 100 50
Sh. flexneri 4a NCTC 24, Sh. sonnei NCTC 9774, V.cholerae 713, 820 100 100 100
S. aureus ML 16, ML 152, ML 329, ML 358, S. typhi NCTC 59, S. choleraesuis NCTC 36, 37, L. monocytogenes NCTC 7973,
NCTC 10351, NCTC 11994
200 200 100
B. subtilis ATCC 6633, B. pumilus NCTC 8241, S. aureus ML 266, ML 358, ML 422, E. coli K12 Row, E. coli C600, S. berta NCTC 69,
S. abony NCTC 6017
200 200 100
B. polymyxa NCTC 4747, B. licheniformis NCTC 10341, S. London NCTC 76, S. enterica serovar Typhimurium NCTC 11, NCTC 74 500 500 500
S. aureus ML 277, V. cholerae 137/62 1000 1000 1000
K. pneumoniae ATCC 10031, K. oxytoca ATCC 130988 2000 2000 2000
L. monocytogenes AMRI 3, A. boumannii KPC 470, 517, P. aeruginosa ATCC 27853, ATCC 25619, C/1/5, Kr/8/89, BVC 1,2,3,4,5, APC1. .2000 .2000 .2000
doi:10.1371/journal.pone.0057493.t001
Figure 1. The spectrophotometric scanning results show that all four compounds had the same lmax (264 nm). HPLC result: The
chromatogram of the four different samples having the same retention time about 4.6 mints indicating that the compounds are identical except for
chirality.
doi:10.1371/journal.pone.0057493.g001
Enantiomers of Thioridazine In Vitro and In Vivo
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e57493
agar (NA, Oxoid), brain heart infusion agar (BHA), Oxoid and
Mueller Hinton agar (MHA), Oxoid); pH was always maintained
at 7.2 to 7.4.
Inoculum
Each bacterium was grown in NA/MHA at 37uC, harvested at
stationary phase and suspended in 5 ml sterile distilled water.
Turbidity of each suspension was matched against 0.5 McFarland
standard [14] along with a spectrophotometer at 625 nm
corresponding to 2.46105 colony forming unit (CFU)/ml.
Determination of Minimum Inhibitory Concentration
(MIC) of the Enantiomers and the Racemate of Tz
This was carried out according to the guidelines of Clinical and
Laboratory Standards Institute (CLSI) [24] by spotting 105 CFU
contained in a 2 mm loop from diluted 18 h broth cultures on
plates containing 0 (control), 50, 100, 200,500, 1000 and 2000 mg/
ml of a drug. The plates were incubated at 370 C, observed for
appearance of growth after 24 h and again after 72 h.
Spectrophotometry
A stock solution containing 1 mg/ml of thioridazine HCl
(Sigma), racemic mixture of thioridazine HCl, dextrorotatory
thioridazine HCl (+) and levorotatory thioridazine HCl (2) were
prepared by dissolving these separately in methanol. Each stock
solution was further diluted to 10mg/ml of methanol. Aliquots of
this solution were taken in a quartz cell and scanned for lmax in
the range of 200–600 nm using methanol as the blank in a double
beam UV spectrophotometer (Jasco-V630). The maximum
absorbance was determined by using Spectra manager (Version-
2.05.03).
HPLC Parameter
Name of HPLC: Jasco.
Column: C8, 25064.6 mm, 5 m particle size.
Flow Rate: 1.0 ml/min.
Loop size: 50 m lit.
UV Absorption: 264 nm.
Mobile Phase: Methanol: Water containing 0.1% v/v
phosphoric acid.
Run Time: 8 mins.
Software used: Clarity lite (Version: 2.6.4.402)
All the samples were prepared as per the above method and
each sample was diluted by methanol (HPLC Grade).Water was
used for the analysis was MilliQ water.
Animal Experiments
Swiss albino male mice each weighing 18–20 gm were selected
for this work. This study was approved by the Institutional Animal
Ethics Committee (IAEC) of Jadavpur University and TAAB
Biostudy Services. Animals were maintained under standard
conditions of temperature (2461uC) and relative humidity (50–
60%) with a photoperiod of 14:10 h of light:dark. Water and a dry
pellet diet were provided ad libitum. The animals were checked
regularly for their health and diet according to the rules and
guidelines set by the Ethical Committee at definite intervals of time
of 12 hr at 8 A.M. in the morning and 8 P.M. in the evening. The
animals which showed symptoms of illness were carefully
observed, identified and were separated from the healthy ones.
These animals were not included in our experiments and were
given proper treatment.
The intensity of virulence of infection caused by Salmonella
enterica serovar Typhimurium 74 and the median lethal dose (MLD
or LD50) of the mouse-passaged strain was as described earlier
Figure 2. The chromatogram showing that all four different samples had the same retention time (about 4.6 min).
doi:10.1371/journal.pone.0057493.g002
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[14,25]. Protective efficacies of the forms of Tz in mice infected
with virulent S. enterica were carried out as described below. Four
groups of animals with 60 mice in the control group and 20 mice
each in the 6 experimental groups were taken. The control group
received 0.1 ml of sterile saline while for each form of Tz there
were 40 animals, in which 20 mice received 100 mg and the other
20 received 200 mg of the drug. After 3 h all the animals were
infected with 50 MLD of virulent S.enterica 74 as described [25].
Protective capacity of all 3 forms of Tz was determined by
recording the mortality of mice in the different groups upto 100 h
after the challenge. The animals which survived after 100 hr of
infection were euthanased with the help of cervical dislocation as
suggested in the Ethical Committee. The end point for performing
euthanasia was observation upto 100 hr with regular monitoring
at 12 hr intervals. The animals which were euthanased prior to
100 hr were based on the condition of their health. Generally
within 72 hr if they showed severe signs of illness, for example loss
of appetite, weight loss, lack of movement, breathlessness,
shivering etc. they were euthanased as advised by the veterinary
doctor in the Ethical Committee The number of animals
euthanased prior to 100 hr varied from 2–7 in each group.
Assessment of the animals euthanized prior to 100 hr was
monitored by the veterinary doctor after every 12 hr as mentioned
8 AM in the morning and 8 PM in the evening.
Determination of the Effect of Treatment by 3 Forms of
Tz on CFU of S. enterica 74 from the Liver, Spleen and
Heart Blood of Infected Mice
In a separate experiment 4 groups of 5 mice each were given the
following treatment: Group 1 was administered 0.1 ml saline while
the other 3 groups received 200 mg each of racemic or (+) or (2)
forms of Tz. After 3 h all the animals were challenged with
50 MLD of the same organism. After 18 h mice in each of the 4
groups were sacrificed by cervical dislocation (as recommended by
the Ethical Committee) and their spleens and livers were
aseptically removed; heart blood was drawn directly from the
heart with the help of a micro-syringe for determination of CFU.
The spleens and livers were homogenized separately in a tissue
homogenizer maintained at 4uC and each specimen was processed
for CFU counts.
Statistical Analysis
The results were statistically evaluated by students ‘t’ test and x2
test wherever applicable, Using freely available statistical software
GraphPad (www.graphpad.com).
Results
Bacterial Inhibitory Spectra of 3 Different Forms of Tz
A total of 55 different Gram positive and Gram negative
bacteria when tested against the 3 forms of Tz, racemic, (+) and
(2), it was found that S. aureus NCTC 6571, V. cholerae 569B, 1023
could be inhibited at 25 mg/ml of each agent (Table 1). Among
others it was found that strains of S. aureus, V. cholerae and shigellae
were also sensitive to these agents MIC of racemic, (+) and (2)
forms of Tz produced almost identical type of inhibition in such
organisms. However, (+) variety was less inhibitory than the other
two. Strains of S. enterica serovar Typhimurium were inhibited at
500 mg/ml of all the compounds. L. monocytogenes NCTC 7973,
NCTC 10351, NCTC 11994 were inhibited at 200mg/ml of
racemic and (+) forms and at 100mg/ml of (2) form. The strains of
Table 2. Effects of 3 forms of thioridazine (Tz) [racemic, (+), (2)] on survival of mice challenged with Salmonella enterica serovar
Typhimurium NCTC 74a.
Control group (not receiving Tz) Test groups (receiving Tz)
Saline (ml/mouse)
No. of mice died
(N=60) Mortality % Tz (mg/mouse)
No.of mice died
(N=20) % survived
0.1 52 86.7 Racemic 100 200* 9 1 55 95
(+) 100 200 12 6 40 70
(2) 100 200* 7 0 65 100
aMice received a challenge of 0.956109 colony-forming units of S. enterica NCTC 74 in 0.5 ml of brain-heart infusion medium.
*p,0.001 vs. controls (x2 test).
doi:10.1371/journal.pone.0057493.t002
Table 3. In vitro activity of sera obtained from blood and homogenates of liver and spleen of mice treated for Salmonella enterica
74.
Group Treatment CFU/ml
b
Sera Homogenate
Heart blood Liver Spleen
Control 0.1 ml of a sterile saline 1.86108 to 5.96108 6.56108 to 9.26108 1.66108 to 8.76108
I 200 mg of Racemic form 9.06104 to 6.66105 2.86103 to 3.86104 2.56103 to 4.86104
II 200 mg of (+) form 3.66104 to 9.66105 2.26104 to 5.06105 7.86103 to 2.86105
III 200 mg of (2) form 1.06103 to 8.06105 2.06103 to 4.76104 1.86103 to 5.76104
aMice received a challenge of 0.956109 colony-forming units of S. enterica NCTC 74 in 0.5 ml of brain-heart infusion medium.
*p,0.001 vs. controls (‘t’ test).
doi:10.1371/journal.pone.0057493.t003
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klebsiellae, P. aeruginosa and L. monocytogenes AMRI 3 were highly
resistant to all the compounds.
UV Spectrophotometer analysis. Maximum absorbance
(lmax) of the 3 forms of Tz and the reference thioridazine (Sigma)
were found to be 264 nm. All the four analytes had the same
absorbance as well as identical absorption spectra (Fig. 1).
HPLC analysis. The chromatogram of the three forms of Tz
and the reference Tz from Sigma had the same retention time
(4.6 min). All the chromatograms were identical showing peaks at
the same concentration (Fig. 2).
In vivo Experiments
Virulence of the infection produced by S. enterica NCTC 74 is
being presented in Table 2. In a control group of 60 mice that
received only the challenge the mortality was 86.7%. As the
number of CFU of S.enterica 74 injected intraperitoneally into mice
increased, the % mortality increased, becoming 100% with a dose
of 0.956109 CFU (Table 2). The protective capacity offered by the
3 different forms of Tz shows that there was 100% survival with
200mg/mouse with the (2) form. With the (+) variety the survival
was 70% with 200 mg/mouse dose. However, racemic proved to
be better than (+) as there was 95% survival with 200mg/mouse
dose (Table 2). It may be mentioned here that the animals that
received (2) form went to sleep within a few minutes after
intraperitoneal injections. Animals of the other two forms went to
sleep after 30–40 minutes of intraperitoneal injection of the
compounds.
The tests on the 3 forms of Tz in mice infected with S.enterica 74
revealed that 5 animals which received only saline and challenge
had .108 live cells in liver, spleen and blood after 18 hr infection.
However, the number of CFUs in all the organs were between 103
and 104, being much less in the test batches of mice that received
one of the 3 drugs along with challenge. The data were statistically
significant (Table 3).
Discussion
Results obtained in the present study show that racemic, (+) and
(2) forms of Tz did not have much difference in their in vitro
action, only except that (2) form had shown slightly better
inhibitory activity than the other two. Standard strains of
L.monocytogenes, eg. NCTC 7973, 10351, 11994 could be inhibited
at 500 mg/ml of the 3 forms of Tz, while L.monocytogenes AMRI 3
that was isolated from an acute systemic infection in Kolkata was
highly resistant to all the drugs. Both the spectrophotometric and
HPLC studies carried out with the 3 forms along with standard
thioridazine from Sigma Chemicals, Denmark showed that there
was no difference in the lmax and that absorption spectra were
identical.
This study further revealed that administration of any form of
Tz successfully protected the mice infected with virulent S.enterica
from lethality. The protection offered by the drugs were also
statistically significant as evidenced by the reduction in the viable
cell count in the organs of infected mice compared to the animals
that were not administered any drug.
Intraperitoneal infection by S.enterica in mice is likely to cause
phagocytosis by neutrophils [24]. According to Gunn [26]
salmonellae can efficiently resist the action of hydrolases due to
the action of PmrA/B regulon responsible for inactivation of
hydrolases. The MIC of all the compounds with respect to
S.enterica 74 was 500 mg/ml and is equivalent to weight of water,
The amount of Tz forms in a mouse receiving 200 mg dose each
would be equivalent to 10 mg/ml, which is one-twentieth of the
actual MIC value. Such a distinct protection by Tz forms in mice
may be explained by the studies of Ordway et al [27].Since these
authors could demonstrate that phenothiazines get concentrated
100 fold inside macrophages maintained in a suitable medium, it
may be possible that the concentration takes place inside the
lysozome leading to rupture of bacterial cell wall. Furthermore as
the phenothiazines are known to promote loss of 55 kD protein
[28], there may have been a significant reduction of virulence of
bacterial cells in the phagolysozome and hence the lethality might
have diminished distinctly. In absence of a direct proof regarding
the actual mechanism of action of the different forms of Tz, the
protection offered by these compounds remains an assumption.
Although it may not be possible to recommend Tz alone against
bacterial infections on the basis of our observation in the present
study, it may be suggested that structural modifications of the
original Tz molecule may open up an avenue on the possibilities of
producing highly potent protective antibacterial agents in course
of time.
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